According to one study, convalescent plasma from recovered COVID-19 patients can dramatically improve the survival potential of hematological cancer patients hospitalized with the deadly virus.
A study led by researchers at the University of Washington in the United States found a 48% reduction in the risk of death for COVID patients with blood cancer who received convalescent plasma compared to similar patients who did not receive this treatment. Is shown.
The survival benefit of convalescent plasma was even greater in patients admitted to the intensive care unit (60% reduction in mortality risk) and in patients requiring mechanical ventilation (68% reduction in mortality).
“These results may not only help patients with COVID-19 who have a blood cancer whose immune system is impaired, but also patients with other diseases whose antibody response to this virus or vaccine is weakened. It suggests that it may not be possible, “said Jeffrey. P. Henderson, an associate professor of medicine and molecular microbiology at the University School of Medicine in St. Louis.
“The study also emphasizes the value of antibody therapies such as convalescent plasma as a virus-oriented treatment option for hospitalized COVID-19 patients,” Henderson added. The survey results are published in the journal JAMA Oncology.
This treatment provides plasma (a pale yellow liquid in the blood rich in antibodies) from people who have recovered from COVID-19 to patients with leukemia, lymphoma, or other blood cancers who are hospitalized for viral infections. Includes blood transfusion. The goal is to accelerate the reaction to fight their illness. Cancer patients may be at increased risk of death associated with COVID-19 due to a weakened immune system.
The team studied 143 patients who received convalescent plasma and 823 patients who did not. Of the 338 patients admitted to the ICU for severe COVID-19 symptoms such as dyspnea and heart pain, treated patients were more than twice as likely to survive.
In March 2020, the US Food and Drug Administration (FDA) approved convalescent plasma therapy for COVID patients at the request of physicians.
Last month, the Indian Medical Research Council (ICMR) discontinued plasma therapy as COVID-19 treatment, but with no significant benefit.
Studies say plasma therapy increases survival in patients with COVID of blood cancer
Source link Studies say plasma therapy increases survival in patients with COVID of blood cancer